Upgrade to SI Premium - Free Trial

Cadrenal Therapeutics (CVKD) PT Lowered to $13 at H.C. Wainwright

April 7, 2026 11:34 AM

H.C. Wainwright analyst Joseph Pantginis lowered the price target on Cadrenal Therapeutics (NASDAQ: CVKD) to $13.00 (from $32.00) while maintaining a Buy rating.

Categories

Analyst PT Change